Acupuncture for Pain Management in Lymphoma

Recruiting at2 trial locations

Overseen by Gary Deng, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.

Research Team

Gary Deng, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for adults over 18 who are scheduled for high-dose chemotherapy and stem cell transplant within a month, diagnosed with Multiple Myeloma (MM), Hodgkin's Lymphoma (HD), or Non-Hodgkin's Lymphoma (NHL). They shouldn't be regular opioid users or have had acupuncture recently. People with very low white blood cells, platelets, or certain clotting issues can't join.

Inclusion Criteria

I haven't taken opioids regularly in the last week.

I am scheduled for a stem cell transplant within the next month.

I am 18 years old or older.

Exclusion Criteria

Your blood tests show very low levels of infection-fighting white blood cells or blood-clotting platelets, or your blood takes longer than normal to clot.

I have not had acupuncture in the last two weeks.

I am unable to understand and agree to the study's details on my own.

Treatment Details

Interventions

• Acupuncture (Other)
• Opioid (Opioid Analgesic)

Trial Overview The study tests if acupuncture can reduce the need for opioids in managing chemotherapy-induced pain in myeloma and lymphoma patients. It compares usual pain management plus acupuncture to usual care alone, also looking at other symptoms and quality of life impacts.

Participant Groups

Group I: Usual Care plus Acupuncture Experimental Treatment 3 Interventions

Acupuncture will start on Day 0 and continue once daily to Day 15, as long as the patient is inpatient or comes to the clinic for post-transplantation follow-up. to prevent severe pain. If acupuncture does not prevent severe pain, the participant will receive opioid medication as backup pain relief.

Group II: Usual Care Active Control 2 Interventions

Will receive only the usual pain management approach, which includes opioid medication when needed for severe pain, according to the routine guidelines for their care.

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Patient-Centered Outcomes Research Institute

Collaborator

Trials

592

Recruited

27,110,000+

Nakela L. Cook

Patient-Centered Outcomes Research Institute

Chief Executive Officer since 2020

MD, MPH

Harv Feldman

Patient-Centered Outcomes Research Institute

Chief Medical Officer

MD, MSCE

Hackensack Meridian Health

Collaborator

Trials

141

Recruited

42,900+

Dr. Gregory J. Rokosz

Hackensack Meridian Health

Chief Medical Officer since 2023

DO from New York College of Osteopathic Medicine, JD from Seton Hall University School of Law

Robert C. Garrett

Hackensack Meridian Health

Chief Executive Officer since 2016

Bachelor's degree in Health Administration from Washington University in St. Louis